Skip to main content
https://pbs.twimg.com/media/G4Gle6YWUAAizpw.jpg
Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a
Richard Conway
26-10-2025
×